Memphasys Reproductive Biotechnology

Memphasys Reproductive Biotechnology is an Australian-based bio-separations company that is developing the Felix device, which is a unique technology aimed at quickly separating high-quality sperm from a semen sample for use in human IVF procedures. The global fertility rates are declining, making technologies such as IVF increasingly common. The industry is anticipated to be valued at over US$26 billion by 2026. However, current methods for sperm cell preparation are inefficient, costly, and time-intensive. The Felix device represents a new approach to selecting the best cells and has been developed in partnership with renowned fertility expert Professor John Aitken. The device uses a technology known as electrophoresis, applying a gentle electrical force through a cartridge containing a semen sample. This process is non-invasive, fully-automated, and can be completed within 6 minutes, significantly increasing the likelihood of a successful pregnancy with a healthy baby. Memphasys is in the process of commercializing the Felix device, with sales anticipated in mid-late 2020 in early access markets, such as Japan, India, Canada, and New Zealand. The company is also exploring the potential of using the technology on animal cells, including equine, bovine, and ovine samples. Overall, the innovative technology and the commercialization plans make Memphasys Reproductive Biotechnology a promising investment opportunity in the rapidly growing reproductive biotechnology market.